Great talk on how we might de-escalate therapy in advanced prostate cancer cases based on profiling plus response #focus23 #stampede MRC Clinical Trials Unit at UCL The ICR

Opening session @FOCUS_meeting #Focus23 🇬🇧🇫🇷 De-escalation in the field of GU cancers. ✅ Trials and biomarkers needed for PCa 👌 AttardLab ✅ The treatment must not be worse than the disease 🙏 François Audenet ✅ Yohann Loriot key questions in germ cells tumors, great overview 🤝

The ESMO - Eur. Oncology LBAs are out And a wow for PEMBRO/EV (Presidential) OS 31.5 vs 16.1 months (HR 0.45) PFS 12.5 vs 6.3 months (HR 0.47) P<0.00001 A historic change for 1L mUC since Von Der Maase JCO 2000 Tom Powles #ESMO23 OncoAlert

🇫🇷 DARIUS PHASE 2 STUDY. 🙏🙏 23/62 patients 🙏🙏🙏 Thanks a lot to all participating Centers! 💯 A real #prostatecancer patients dedicated trial. Roubaud Guilhem GETUG Association Française d'Urologie - AFU @sfro_fr ESTRO ASTRO EORTC @BERGONIE33

I would like to thank all the patients, investigators, institutions, protocol team members, NRG Oncology, NCICancerTrials, and many others who helped with NRG LU002. We made incredible history in successfully randomizing to the largest OMD NSCLC trial to date evaluating local therapy

Proud of this achievement..finally!#PhD Thanks to the wonderful lab team AYYOUB LAB headed by Prof Ayyoub for their great support!🙏🏼 CRCT-Oncopole

Our latest study with Piet Ost, of whole prostates, lymph nodes, and ctDNA at initial diagnosis in de novo metastatic prostate cancer (distant mets) is out in Nature Cancer: rdcu.be/du8Tu. 1/n thread 👇

1/N Finally out!! -- 30Gy for HPV+OPC in Journal of Clinical Oncology – work by the Memorial Sloan Kettering Cancer Center Head and Neck team, led by Nancy Lee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JC…

A much needed study to find out the best care for our patients. Dr. Tsai is a thought leader.

📢The long awaited, highly anticipated #RedJournal issue on Combinatorial Therapies is out🔥‼️ So many AMAZING reviews & original articles👏🙏Where to begin❓ #RTdrugcombo Salma Jabbour et al. redjournal.org/article/S0360-… RT/IO Amy Wisdom, MD, PhD et al. sciencedirect.com/science/articl… PARPi/RT

Final results from PACIFIC-2 (Durvalumab in combination with CRT vs CRT + placebo) for patients with unresectable stage III NSCLC. No improvement on PFS and OS. Tumor antigenic priming by RT is likely required to subsequently benefit from IO. #ELCC24 OncoAlert Jonathan Khalifa 🎗️

👀👀Au 2 ème jour, les 400 yeux des participants sont cernés mais la dynamique est la même lors du GFRU à Bordeaux. On discute vessie, rein, prostate... 👌

DARIUS trial protocol is online in European Urology Oncology ▶️Phase 2 randomized ▶️ Unfavorable intermediate risk prostate cancer ▶️ Radiotherapy + stADT Versus an ADT sparing approach using stDarolutamide ▶️58/62 patients included... ▶️PSA End as 1st objective sciencedirect.com/science/articl…

DARIUS trial results for patients with unfavorable intermediate risk PCa to be reported in 2025... GETUG Association Française d'Urologie - AFU Jonathan Khalifa 🎗️ ESTRO Decipher by Veracyte Ulrike Schick

« There is a crack in everything That’s how the light gets in », #happyhanukkah #happynewyear

Congratulations Patrick Forde . Great News 👍 👌. Checkmate 816 shows OS benifit. Now if 3 cycles of Neoadjuvant IO shows OS benifit, then we need to be more selective about whom to give additional adjuvant IO . Stephen V Liu, MD Sandip Patel MD FASCO M. Bolton Jarushka Naidoo Alfredo Addeo MD

🧡🧡🧡

#astro25 NRG Oncology Rtog 0924 trial on 2500 patients testing whole pelvic RT. Negative trial -OS no difference -PCSM no difference -DM no difference -BCR was not SS different with only 4% difference at 10 years. -toxicity increased 3 cooperative group trials now negative: